Cardiff Oncology Inc (CRDF) Stock Price, Quote & News

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative brea...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 952 7570

Website: www.cardiffoncology.com

Address:

11055 Flintkote Avenue, San Diego, United States

jrh34 Mar. 21 at 7:30 PM

$CRDF There's a battle being waged behind the scenes for control of the company and rights to Onvansertib. It's good to have something others want.

1 · Reply

BubbaLubsGreen Mar. 21 at 6:04 PM

$CRDF friends, I have seen a few new names here recently and at least one was honest enough to simply ask for guidance about Cardiff Oncology's present situation. In case there are others here are just starting their due diligence, here are the absolute most essential things to know about this stock: 1. Cardiff Oncology is a pre-commercial, micro cap biotechnology company with a single FDA candidate in trials, a drug called Onvansertib. 2. Onvansertib is the property of Nerviano Medical Sciences (NMS) in Italy and is licensed to CRDF. 3. The FDA meeting planned for 2026 will be a pivotal moment for the stock, since the desired phase 3 registrational trial depends on a positive outcome of that meeting. 4. Data is awaited, and the next full update on trial data is also a pivotal moment for the stock. 5. The company has a cash runway into 2027 but will need to convince the market that it has a realistic path toward full funding of the phase 3 trial.

0 · Reply

biohuntress Mar. 20 at 9:11 PM

$CRDF somebody emphasized Onva has unique potential when combined with ADC's that have TOPO 1 inhibitors....so kind of confirms this will be be the next direction beyond Bev combos https://www.abstractsonline.com/pp8/#!/21436/presentation/4405

1 · Reply

Blakeruss1 Mar. 20 at 8:49 PM

$CRDF strongest stock in USA Today.

1 · Reply

mgmuc Mar. 20 at 7:32 PM

$CRDF .. from LinkedIn

0 · Reply

BubbaLubsGreen Mar. 20 at 6:24 PM

$CRDF has, for reasons beyond my comprehension, not been given very much press in medical journals during the six years I've been an investor in the company. I believe something important has been largely ignored, and that is the well known role that PLK-1 plays in a number of deadly cancers. The word "platform" has been used quite often here recently. I believe it's a word that someone new to the Onvansertib story might not immediately associate with an unapproved treatment. But when you do your due diligence into the array of cancers that could foreseeably be treated with a safe, highly targeted inhibitor like Onvansertib, the word makes a lot more sense.

1 · Reply

jakeguess Mar. 20 at 5:57 PM

$CRDF red to green comeback to end day.

0 · Reply

biohuntress Mar. 20 at 5:13 PM

$CRDF they will have to disclose they are paid SAB members...both are heavyweights....this is what is needed to elucidate the full potential of Onva in many indications

1 · Reply

Teskonik Mar. 20 at 4:19 PM

$CRDF

1 · Reply

Core366 Mar. 20 at 3:21 PM

$CRDF Lets see what the KOL's input is

0 · Reply

Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer

Mar 19, 2026, 7:00 AM EDT - 2 days ago

Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

Feb 26, 2026, 4:01 PM EST - 23 days ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Feb 24, 2026, 4:30 PM EST - 25 days ago

Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

Feb 19, 2026, 7:00 AM EST - 4 weeks ago

Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 28, 2026, 6:23 AM EST - 7 weeks ago

Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus

Jan 28, 2026, 2:12 AM EST - 7 weeks ago

Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript

Jan 27, 2026, 7:05 AM EST - 7 weeks ago

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Jan 27, 2026, 7:00 AM EST - 7 weeks ago

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

CTMX

Jan 13, 2026, 10:48 AM EST - 2 months ago

Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm

Dec 8, 2025, 4:05 PM EST - 3 months ago

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Dec 8, 2025, 7:00 AM EST - 3 months ago

Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference

Nov 24, 2025, 7:00 AM EST - 4 months ago

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 6, 2025, 4:05 PM EST - 4 months ago

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

Nov 4, 2025, 4:01 PM EST - 4 months ago

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Oct 25, 2025, 7:50 AM EDT - 5 months ago

Cardiff Oncology: Preparing For A Defining 2026

Oct 22, 2025, 7:45 AM EDT - 5 months ago

Cardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To Buy

Aug 28, 2025, 4:05 PM EDT - 7 months ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Jul 30, 2025, 3:27 PM EDT - 8 months ago

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Jul 30, 2025, 11:32 AM EDT - 8 months ago

Cardiff Oncology: Data Update Resolves Some Signals

Jul 29, 2025, 4:07 PM EDT - 8 months ago

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Jun 27, 2025, 8:30 AM EDT - 9 months ago

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Jun 17, 2025, 4:39 PM EDT - 9 months ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:05 PM EDT - 9 months ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Jun 2, 2025, 4:05 PM EDT - 10 months ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

May 14, 2025, 9:05 AM EDT - 11 months ago

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

May 8, 2025, 4:05 PM EDT - 11 months ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 2, 2025, 3:35 AM EDT - 11 months ago

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

Apr 23, 2025, 4:05 PM EDT - 11 months ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 15, 2025, 4:10 PM EDT - 1 year ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Feb 27, 2025, 9:10 PM EST - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 24, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 20, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Feb 18, 2025, 9:19 AM EST - 1 year ago

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Dec 14, 2024, 9:00 AM EST - 1 year ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

UI VOD DE ESPR FLNC GASS HII

Dec 12, 2024, 5:38 AM EST - 1 year ago

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Dec 10, 2024, 5:05 PM EST - 1 year ago

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Dec 10, 2024, 7:20 AM EST - 1 year ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 6:00 AM EST - 1 year ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Oct 4, 2024, 1:10 PM EDT - 1 year ago

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Aug 12, 2024, 2:57 PM EDT - 1 year ago

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Aug 10, 2024, 11:18 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

May 29, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 21, 2024, 11:22 PM EDT - 1 year ago

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

May 13, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 3, 2024, 1:30 AM EDT - 2 years ago

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 2 years ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

jrh34 Mar. 21 at 7:30 PM

$CRDF There's a battle being waged behind the scenes for control of the company and rights to Onvansertib. It's good to have something others want.

1 · Reply

BubbaLubsGreen Mar. 21 at 6:04 PM

0 · Reply

biohuntress Mar. 20 at 9:11 PM

1 · Reply

Blakeruss1 Mar. 20 at 8:49 PM

$CRDF strongest stock in USA Today.

1 · Reply

mgmuc Mar. 20 at 7:32 PM

$CRDF .. from LinkedIn

0 · Reply

BubbaLubsGreen Mar. 20 at 6:24 PM

1 · Reply

jakeguess Mar. 20 at 5:57 PM

$CRDF red to green comeback to end day.

0 · Reply

biohuntress Mar. 20 at 5:13 PM

$CRDF they will have to disclose they are paid SAB members...both are heavyweights....this is what is needed to elucidate the full potential of Onva in many indications

1 · Reply

Teskonik Mar. 20 at 4:19 PM

$CRDF

1 · Reply

Core366 Mar. 20 at 3:21 PM

$CRDF Lets see what the KOL's input is

0 · Reply

mark31 Mar. 20 at 1:49 PM

$CRDF in here 1.84 swing april no far away

1 · Reply

BullRun4 Mar. 20 at 1:46 PM

$CRDF Onvansertib is not just a PLK1 inhibitor It is a “payload amplifier” for DNA-damaging therapies! Onvansertib is evolving from a “single-indication oncology drug” into a combination backbone that enhances other blockbusters! Could Onvansertib be the new Keytruda?

0 · Reply

Blakeruss1 Mar. 20 at 1:34 PM

$CRDF going parabolic

1 · Reply

ST_Stefan Mar. 20 at 1:16 PM

$CRDF Why schedule a KOL webinar if you're not bullish? If it's not good news, just wait until after FDA meeting.

2 · Reply

Quinn1614 Mar. 20 at 1:13 PM

$CRDF what do people think of the news?

0 · Reply

Cutlass Mar. 20 at 12:42 PM

$CRDF Should provide some interesting optics for the board over the next 4 days as Shorty 👕decides whether to de-risk somewhat or not . . . tick tock ⏰

1 · Reply

frogman2000 Mar. 20 at 12:30 PM

$CRDF pretty interesting assessment by both Claude and ChatGPT when you post next week‘s webinar announcement and juxtapose that with the Nerviano grievance. Both essentially have the same assessment, which is that Cardiff boldness and being in public about the value of what they have either demonstrates or the issue is resolved or a deal is so far along that the license agreement is being wrapped into some sort of deal. Pretty interesting that both jumped that same conclusion

0 · Reply

rag2riches Mar. 20 at 12:12 PM

$CRDF exciting!!!

0 · Reply

frogman2000 Mar. 20 at 12:07 PM

$CRDF Before a large pharma acquirer can defend a premium acquisition price internally, the asset needs to be legible to a broader investor audience. A KOL webinar with Kopetz and Lenz effectively sets a public market “floor” for how the medical community values onvansertib. It’s the kind of move a banker or acquirer would encourage Cardiff to make in the weeks before an announcement — it compresses the post-announcement debate about whether the science is real. The timing (March 25, five weeks before the April 19 Nerviano cure window) fits a Q2 announcement cadence.

1 · Reply

Cutlass Mar. 20 at 11:18 AM

$CRDF For more information, please visit https://www.cardiffoncology.com. Investor Contact: Candice Masse Astr Partners [email protected] Media Contact: Amy Bonanno Lyra Strategic Advisory [email protected]

0 · Reply

Cutlass Mar. 20 at 11:16 AM

$CRDF Cardiff Oncology, Inc. (CRDF) , a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will host a key opinion leader (KOL) webinar to discuss the emergent treatment landscape in first-line RAS-mutated metastatic colorectal cancer (mCRC). The webinar will take place on Wednesday, March 25th, 2026, at 4:30 p.m. ET. The webinar will feature KOLs Scott Kopetz, M.D., Ph.D., FACP and Heinz-Josef Lenz, M.D., who will join Mani Mohindru, PhD, interim Chief Executive Officer, to discuss onvansertib's existing clinical data and its potential as a novel therapeutic approach in the management of mCRC.

2 · Reply

DARKP00L Mar. 20 at 11:04 AM

$CRDF 07:03 on Mar. 20 2026 Cardiff Oncology To Host Key Opinion Leader Webinar To Discuss Emergent Treatment Landscape In First-Line RAS-Mutated Metastatic Colorectal Cancer On March 25 #tradeideas

0 · Reply

Market Cap	123.06M
Revenue (ttm)	590,000.00
Net Income (ttm)	-45.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,771.19%
Debt to Equity Ratio	0.00

Volume	429,300
Avg Vol	1,157,454
Day's Range	N/A - N/A
Shares Out	68.37M
Stochastic %K	22%
Beta	1.32
Analysts	Strong Sell
Price Target	$8.36